Abstract 445P
Background
Nasopharyngeal cancer (NPC) is notably prevalent in Southeast Asia, including Hong Kong. The survival rate of NPC patients has improved over the past decade. However, the emergence of various late radiation side effects during survivorship remains a concern. While the clinician-reported incidence of symptoms has been reported, a comprehensive assessment of self-reported symptoms is still lacking. This study aims to examine the subjective symptom burden, quality of life, and unmet needs among local NPC survivors.
Methods
A single-centre cross-sectional survey was conducted at a local public hospital, including 200 NPC survivors who had completed radiation therapy (RT) with or without chemotherapy for three to 120 months. We employed the Chinese version of three questionnaires: M. D. Anderson Symptom Inventory - Head & Neck Module (MDASI-HN), Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN), and Cancer Survivors’ Unmet Needs Measure (CaSUN).
Results
Survivors experienced, on average, more than four moderate to severe symptoms (Mean [M] ± SD = 4.84±4.99), with no association found with post-RT time (p = 0.443). The top five severe symptoms were dry mouth (M±SD = 5.47±2.90), mucus problem (M±SD = 4.27±3.17), dysphagia (M±SD = 3.38±3.03), teeth/gum problems (M±SD = 2.98±3.17), and poor memory (M±SD = 2.94±2.63). The mean scores of the top five symptoms were used to represent the symptom burden, which was negatively associated with the physical (F(1,198) = 139.783, p < 0.001, R2 = 0.414), emotional (F(2,197) = 38.303, p < 0.001, R2 = 0.280), additional concerns (F(1,198) = 85.993, p < 0.001, R2 = 0.303) subscales, and the total scores (F(2,197) = 33.083, p < 0.001, R2 = 0.251) of the FACT-HN. The unmet need for symptom management by CaSUN was positively associated with symptom burden (OR = 1.379, 95% CI [1.185, 1.604], p < 0.001), while negatively associated with post-RT time (OR = 0.981, 95% CI [0.972, 0.991], p < 0.001).
Conclusions
NPC survivors suffer from symptoms irrespective of the time elapsed post-RT. The observed varying unmet need for symptom management necessitates further exploration into supportive care for cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract